Serum levels of il-6 and crp can predict the efficacy of mfolfirinox in patients with advanced pancreatic cancer

HIGHLIGHTS

• who: Feifei Shen from the United States University of Illinois at Chicago have published the research work: Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer, in the Journal: (JOURNAL)
• what: In this study, the cutoff values were determined using the normal ranges, while previous studies used statistical methods to determine the cutoff.
• how: Multivariate analysis was performed using a stepwise forward Cox regression (likelihood ratio enter P and amplt 0.05 remove P > 0.10) with significant markers from the univariate analyses . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.